In:
Family Practice, Oxford University Press (OUP), Vol. 40, No. 2 ( 2023-03-28), p. 407-413
Kurzfassung:
Despite the frequent use of symptomatic therapies in cough, evidence of their benefits is lacking. Objective We compared the effectiveness of 3 symptomatic therapies and usual care in acute bronchitis. Methods Multicenter, pragmatic, multiarm parallel group, open randomized trial in primary care (ClinicalTrials.gov, Identifier: NCT03738917) was conducted in Catalonia. Patients ≥18 with uncomplicated acute bronchitis, with cough & lt;3 weeks as the main symptom, scoring ≥4 in either daytime or nocturnal cough (7-point Likert scale), were randomized to usual care, dextromethorphan 15 mg t.i.d., ipratropium bromide inhaler 20 µg 2 puffs t.i.d, or 30 mg of honey t.i.d., all taken for up to 14 days. The main outcome measure was the number of days with moderate-to-severe cough. A symptom diary was given. A second visit was scheduled at days 2–3 for assessing evolution, with 2 more visits at days 15 and 29 for clinical assessment, evaluation of adverse effects, re-attendance, and complications. Results We failed to achieve the sample size scheduled due to the COVID-19 pandemic. We finally recruited 194 patients. The median number of days with moderate-to-severe cough (score ≥ 3) in the usual care arm was 5 (interquartile range [IQR], 4, 8.75), 5 in the ipratropium bromide arm (IQR, 3, 8), 5 in the dextromethorphan arm (IQR, 4, 9.75), and 6 in the honey arm (IQR, 3.5, 7). The same results were obtained in the Kaplan–Meier survival analysis for the median survival time of each arm with the usual care as the reference group. Conclusion The symptomatic treatment evaluated has shown to be ineffective against cough.
Materialart:
Online-Ressource
ISSN:
1460-2229
DOI:
10.1093/fampra/cmac112
Sprache:
Englisch
Verlag:
Oxford University Press (OUP)
Publikationsdatum:
2023
ZDB Id:
1484852-1
